3-D MATRIX, LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 119 JPY | -2.46% |
|
-7.75% | -15.00% |
| Sales 2022 | 1.51B 9.74M | Sales 2023 | 2.31B 14.96M | Capitalization | 9.97B 64.44M |
|---|---|---|---|---|---|
| Net income 2022 | -1.89B -12.24M | Net income 2023 | -2.44B -15.81M | EV / Sales 2022 | 13.1 x |
| Net Debt 2022 | 817M 5.28M | Net Debt 2023 | 3.2B 20.71M | EV / Sales 2023 | 5.69 x |
| P/E ratio 2022 |
-9.3
x | P/E ratio 2023 |
-3.87
x | Employees | 108 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 91.48% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.46% | ||
| 1 week | -7.75% | ||
| Current month | -5.56% | ||
| 1 month | -13.14% | ||
| 3 months | -11.19% | ||
| 6 months | -24.20% | ||
| Current year | -15.00% |
1 week
118.00
131.00
1 month
118.00145.00
Current year
101.00154.00
1 year
101.00207.00
3 years
101.00643.00
5 years
101.00762.00
10 years
101.005 100.00
| Managers | Title | Age | Since |
|---|---|---|---|
Tomoyuki Arai
DFI | Director of Finance/CFO | 51 | 08-11-30 |
Jun Okada
PSD | President | 49 | 05-07-31 |
Takao Miki
BRD | Director/Board Member | 47 | 19-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kazuya Shimamura
BRD | Director/Board Member | 51 | 08-06-30 |
Jun Okada
PSD | President | 49 | 05-07-31 |
Keiji Nagano
CHM | Chairman | 69 | 04-05-18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-15 | 122 | -3.94% | 865,400 |
| 24-04-12 | 127 | 0.00% | 213,400 |
| 24-04-11 | 127 | -0.78% | 147,900 |
| 24-04-10 | 128 | -0.78% | 361,200 |
| 24-04-09 | 129 | +1.57% | 204,300 |
Delayed Quote Japan Exchange, April 16, 2024 at 02:00 am EDT
More quotes
3-D Matrix, Ltd. is a company engaged in the research, development, manufacture and sale of medical products. The Company has Medical Product segment. The segment consists of two divisions. The medical product development and sales division is engaged in the research and development of medical equipment and drugs for surgery area, regeneration medicine area and drug delivery system (DDS) area based on the self-organizing peptide technology, including hemostatic, vascular embolization and alveolar bone reconstruction materials, among others. The research reagents sales division is engaged in the sale of medical products based on the self-organizing peptide technology for research and test use in universities and research institutes.
Calendar
2024-06-10
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -15.00% | 62.76M | |
| +48.60% | 42.16B | |
| -0.56% | 42.07B | |
| +5.76% | 39.77B | |
| -11.36% | 26.68B | |
| +4.30% | 24.68B | |
| -22.77% | 18.68B | |
| -1.55% | 12.11B | |
| +26.58% | 11.99B | |
| +5.87% | 11.06B |
- Stock Market
- Equities
- 7777 Stock
